A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

This trial is testing a new type of cancer treatment called an oncolytic virus (R130 OV) — a modified virus that is injected directly into tumors and is designed to selectively destroy cancer cells — for people with recurrent or refractory head and neck cancer that has not spread to distant organs. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with head and neck cancer confirmed by biopsy or cytology - Your cancer has not spread to distant organs - Standard treatment has failed - You have at least one tumor that can be injected with the study drug - Your ECOG score is 0–2 and your expected survival is at least 3 months - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You have had an allergic reaction to similar drugs - You have a blood cancer, a central nervous system tumor, or another active malignancy - You are pregnant or breastfeeding - You have active hepatitis B, hepatitis C, or HIV - You are taking antiviral medications like acyclovir or ganciclovir - You have had cancer treatment within the past 4 weeks Talk to your doctor to see if this trial is right for you.